HTA’s such as AIFA and the Ministry of Health of Russia on achieving greater collaboration and a better understanding of their HTA policies 

HTA, Wednesday 18 March 2020

Registration & refreshments

Morning Plenary

Wendy Jory

Global implications of pricing & access developments in the US


Rerserved for Covance

Bharat Tewarie

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value


Reserved for Life Science Dynamics


Speed Networking


Morning refreshments

David Thompson

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Thomas Mueller

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

round tables


Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock

Kate Adcock, Director of Research and Innovation, The Muscular Dystrophy U.K.

Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter

Michael Schroter, Partner, Viopas Partners

Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian

Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie

Roundtable 14: Indication based pricing- where are we?
Nicki Catterick

Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group

Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oresta Piniazhko

Oresta Piniazhko, Director, HTA Department, Ministry of Health of Ukraine

Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster

Douglas Foerster, Head Market Access Europe And Row, Santhera

Roundtable 17: Working together with NGOs, Advocates, Pharma & Government to improve outcomes for families?
Edmund Lim

Edmund Lim, Co-Founder, We CARE Journey

Roundtable 18: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay

Sagie Pillay, Chief Operating Officer, Wits Health Consortium

Roundtable 19: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch

Sebastian Soluch, Head of Market Access and Pricing, Europe, Stemline Therapeutics Inc

Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos

Chris Pashos, Vice President Of Global Evidence Strategy, AbbVie

Roundtable 20: Branded combo-pricing: Where to next?
Yves Samel

Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer

Roundtable 21: Exploring Patient Access in Belgium: challenges and opportunities
Katrien Van Geyt

Katrien Van Geyt, Head Of Market Access, Belgium And Luxembourg, Takeda

Roundtable 22: Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Marcus Gaurdian

Marcus Gaurdian, Chief Operating Officer, EUnetHTA

Roundtable 23: Exploring orphan drugs in emerging markets
Lisette Kaskens

Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications

Roundtable 24: Developments in pricing and patient access for speciality treatments
Keith White

Keith White, Vice President and Head, Global Market Access, Corbus Pharmaceuticals

Roundtable 25: Reserved for Syneos Health
Roundtable 26: Reserved for Life Science Dynamics
Roundtable 27: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan

Gomathi Kaliappan, Global Market Access (Health Systems Strategy, Value Recognition), Roche

Roundtable 28: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu

Elena Lungu, Manager, Policy Development, Government of Canada (Canada)

Roundtable 29: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Julien Patris

Julien Patris, Associate Director Of Market Access And Policy For Europe And Canada, Alnylam

Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Jolanda Koenders

Jolanda Koenders, Head of Market Access Netherlands, Takeda

Roundtable 30: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich

Adam Plich, Managing Director, Plich Advisory

Roundtable 32: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon

Giovanny Leon, Pricing And Market Access Director For Latin America And Canada, Novartis AG

Roundtable 33: Access and pricing considerations for CAR-T development
Nuno Prego Ramos

Nuno Prego Ramos, CEO, CellmAbs

Roundtable 34: Exploring Free of Charge supply model for an orphan drug at public healthcare coverage in Argentina
Marcelo Sal

Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics

Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Lindsay Weaver

Lindsay Weaver, Chief Executive Officer, Metabolic Support UK

Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo

Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh

Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin

Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement

Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate

Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara


Networking lunch



Innovation in HTA & HTA in Russia

Stephen Hall

Horizon scanning in the HTA process; helping to facilitate UK market access


Sponsor presentation


Stakeholder Engagement and Integrating Evidence

Kevin Rieger

Chair’s remarks

Goedele Van Haasteren

HTA for Switzerland and stakeholder engagement

Arrigo Paciello

Working with AIFA to establish the value of new drug therapies

Mario Ouwens

The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?


Afternoon Refreshment Break



Close of conference and networking drinks reception

last published: 11/Nov/19 14:55

HTA, Thursday 19 March 2020

Morning Plenary


Sponsor presentation

Panel discussion

Morning refreshments


Roundtable 10: How to establish a market access department from scratch?


Roundtable 12: Exploring the international reference pricing landscape


Roundtable 13: Patient Assistance Programs and Access Structure in the US


Roundtable 14: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics


Roundtable 5: Exploring the evolution of the value framework to assess drugs in Italy


Roundtable 7: Exploring Biosimilars in the USA and latest developments


Roundtable 8: Accelerating Access to treatments for Rare Diseases

Rute Fernandes, Head Of Rare Diseases Of Europe And Canada, Takeda

Roundtable 9: How to involve patients in drug research and market access?




Roundtables 1: Innovation in Contracting


Roundtables 2: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes


Roundtables 3: Exploring innovative payment and evidence development models for rare diseases


Roundtables 4: How to improve the environment for value-added medicines in Europe


Networking Lunch


Afternoon Refreshments

last published: 11/Nov/19 14:55

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

To speak:
Chris Shanks
+44 (0)207 092 1151